News

Arbutus Biopharma Engages with Investors at London Conference

Arbutus Biopharma Engages with Investors at London Conference

Arbutus Biopharma Engages with Investors at London Conference

Arbutus Biopharma Corporation (NASDAQ: ABUS) is making strides in the biopharmaceutical industry, focusing on developing innovative therapies for chronic hepatitis B virus (cHBV) infections. Known for its expertise in virology, the company is set to showcase its advancements at an upcoming investor event that promises to foster valuable connections and insights.

Upcoming Investor Conference Presentation

The Jefferies London Healthcare Conference will be a significant opportunity for Arbutus. Scheduled for November 21, 2024, at 12:00 pm GMT / 7:00 am EST, this event includes a fireside chat where company representatives will discuss their ongoing research and development efforts in detail.

Accessing the Live Webcast

For those interested, the live webcast of the fireside chat can be accessed through the Arbutus investor website. Attendees will have the chance to listen to key insights shared by the company. Following the event, the recorded webcast will also be available on their website for catch-up viewing.

About Arbutus Biopharma Corporation

Arbutus Biopharma is driven by a commitment to uncover effective treatments for patients suffering from chronic hepatitis B. This clinical-stage biopharmaceutical company is focusing on levers that can potentially push the boundaries of traditional therapy. Their strategy involves a robust pipeline that showcases unique compounds, including an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor known as AB-101.

Innovative Therapeutics in Development

Imdusiran is currently under investigation in two Phase 2a combination clinical trials. This promising compound has shown encouraging clinical data, illustrating its ability to reduce surface antigen levels and rekindle the immune response specific to HBV. On the other hand, AB-101 is being examined in a Phase 1a/1b clinical trial, highlighting the company's dedication to exploring multiple avenues for cHBV treatment.

Contacting Arbutus Biopharma

For investor relations inquiries or media queries, Lisa M. Caperelli, Vice President of Investor Relations, is available for contact. Interested parties can reach her at 215-206-1822 or via email, providing a direct line to the company’s communication channel.

Frequently Asked Questions

What is Arbutus Biopharma’s main focus?

Arbutus Biopharma focuses on developing therapies for chronic hepatitis B virus (cHBV) infections.

When is Arbutus Biopharma’s conference presentation?

The conference presentation is set for November 21, 2024, at 12:00 pm GMT / 7:00 am EST.

How can I access the live webcast of the presentation?

The live webcast can be accessed through the Arbutus investor website during the conference.

What is the significance of imdusiran?

Imdusiran is a key component in Arbutus’s pipeline, showing potential in reducing surface antigen levels and enhancing immune responses against HBV.

Who can I contact for more information about Arbutus Biopharma?

Lisa M. Caperelli, the Vice President of Investor Relations, can be contacted for more information.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Cboe Global Hits Record Index Options Volume in October

Updated Category News Views 52

October's Market Landscape: Peaks and Troughs Sometimes you look at market reports and it feels like you're staring at a rollercoaster's wild ride. This past October was a month full of twists for Cboe Global Markets, Inc. (Cboe: CBOE). With trading volumes shifting dramatically across its various segments, Cboe delivered some impressive highlights against a mixed...

Continue Reading
MY DR NOW Expands: Seven-Day Clinics Open Everywhere

Updated Category News Views 54

Breaking The Mold Of Traditional Medicine MY DR NOW isn't here to play by the age-old rules. They're slinging open the doors to their newest family medicine clinics and kicking the old Monday-to-Friday scheduling straight to the curb. Every single day of the week, from 8 a.m. to 8 p.m., patients in Sunnyvale and Tucson are getting a dose of healthcare that's all about...

Continue Reading
Zillow Eases the FHA Down Payment Burden

Updated Category News Views 44

A New Financial Lifeline for Homebuyers In a market where finding a foothold in the housing game feels like scaling Everest without ropes, Zillow Home Loans has tossed a lifeline to potential homeowners. Their latest move might just be what many house hunters needed to hear—offering a hand where it’s been missing for years: down payment assistance for FHA loans. The...

Continue Reading
Elite Academy Takes Bold Step in Ethical AI for Schools

Updated Category News Views 97

Pioneering New Fronts in Education with AI Elite Academic Academy, a stalwart in California's public charter school landscape, has just taken a significant stride forward by stepping into the EDSAFE AI Alliance District Policy Lab. The move, announced in early November 2026, sees Elite diving into the intricate world of artificial intelligence in education, with a pointed...

Continue Reading
WellNet Embraces Voice AI for Provider Calls

Updated Category News Views 141

Ever met a TPA grappling over their provider call costs like a crusty sailor with a rusted anchor? Welcome to WellNet Healthcare, folks. They've tapped EHVAhealth's conversational voice AI to take a solid swing at automating those burdensome provider calls. They're no stranger to the chaos of managing member eligibility and benefits verification, and this move might just...

Continue Reading
Hidden Costs of Lineworker and CDL Training in California

Updated Category News Views 71

The True Financial Picture of Skilled Trade Programs Ever wonder why that flashy tuition number doesn't line up with your wallet by the end of your training days? That's the reality smashing aspiring lineworkers and future truck drivers in Northern California right in the face. We're talking about a full breakdown here, beyond what the glossy brochures ever tell you....

Continue Reading
Fedora and Clarion Boost Oncology Practice Performance

Updated Category News Views 72

Hell of a Pair-Up: Fedora and Clarion Focus on Oncology Well, here's a setup that doesn't scream about blue chip stocks—but it's swimming in opportunity all the same. Fedora Healthcare Solutions just shook hands with Clarion, cementing a deal that's piqued my interest for its potential to green-light some real progress for independent oncology practices. These are not...

Continue Reading
Exiger Lands $12M Deal with USAF for ICBM Insights

Updated Category News Views 66

Exiger's New Partnership: A $12M Heavyweight Move The Air Force isn’t about to let its guard down when it comes to those intercontinental ballistic missiles. Nope, the powers that be have decided it’s time to pump some serious dough into the chain that keeps those missiles ready to go, handing $12 million over to Exiger to light the path through the complex web of the...

Continue Reading
Class Action Targets Extremist Groups, Interference

Updated Category News Views 80

Legal Spar on the Horizon: Class Action Commences The legal world now sees a fresh duel as Impresa Legal Group rolls up its sleeves and files a class action lawsuit against certain extremist groups and foreign-funded entities. At the heart of this legal action are accusations that these outfits have orchestrated a campaign to intimidate data center workers while meddling...

Continue Reading
Centrus Energy's Quarter Ups and Downs Unpacked

Updated Category News Views 19

Stirring the Pot: Centrus Energy's Rollercoaster Quarter Trading never fails to serve up surprises, and Centrus Energy Corp. (NYSE:LEU) is dishing them out this quarter. Despite a revenue slip to $55.5 million from last year’s $74.9 million, GAAP net income rocketed to a whopping $31.6 million. Talk about a mixed bag of fortunes. Diving Deeper into the Numbers Revenue...

Continue Reading

Top 5 Most Recently Viewed Articles

Chipotle Celebrates Veterans Day with Special Offer for Heroes

Updated Category News Views 289

Chipotle's Commitment to Honoring Veterans On a special day dedicated to honoring those who have served, Chipotle Mexican Grill is prepared to show its appreciation towards the military community. This Veterans Day, across all participating U.S. locations, Chipotle is offering an excellent opportunity, allowing veterans to enjoy a free entrée when they purchase another,...

Continue Reading
Exploring QIAGEN's Commitment to Newborn Genomic Sequencing

Updated Category News Views 134

Innovating Genomic Sequencing for Newborns QIAGEN (NYSE: QGEN) is making significant strides in the field of genomic medicine by partnering with Genomics England on a remarkable initiative aimed at sequencing the genomes of newborns. This pioneering effort seeks to screen for over 200 genetic conditions, facilitating early diagnosis and intervention for rare health...

Continue Reading
Investors' Call to Action Against XP Inc. Misleading Practices

Updated Category News Views 281

Investors Taking Action Against XP Inc. In recent weeks, concerns have surfaced regarding XP Inc.'s (NASDAQ: XP) potential for misleading business information affecting shareholders. The Rosen Law Firm, known for its dedication to investor rights, is actively investigating these claims. They are urging XP investors to join the movement towards accountability and seek...

Continue Reading
Orvana Hits Snags in Bolivia While Eyeing Growth

Updated Category News Views 5

Orvana's Rollercoaster in Bolivia Here's a little tale about Orvana Minerals Corp. (TSX: ORV) and their bumpy road through Bolivia, and it's got the makings of a real nail-biter. We’re talking about the Don Mario operation here, where the company tussled with hefty logistical disruptions—that is, over 53 days of strikes and blockades. Those hiccups set the company's...

Continue Reading
World Winter Sports Expo 2025: A New Era for the Industry

Updated Category News Views 382

World Winter Sports Expo 2025 Unveils New Opportunities Hello again, world! The World Winter Sports Expo (WWSE) has kicked off its 2025 festivities at the stunning Shougang Park in Shijingshan. This event celebrates a decade since the expo began, evolving into the biggest and most influential platform for the ice and snow industry. The WWSE is uniquely positioned to...

Continue Reading